Amodiaquine

As a core member of 4-aminoquinoline antimalarial drugs, amodiaquine exerts its effects by inhibiting the nucleic acid synthesis of Plasmodium and interfering with its heme detoxification pathway. Its antimalarial activity is significantly better than that of chloroquine, and it remains effective against some chloroquine-resistant parasite strains. It is mainly used clinically for the treatment of falciparum malaria and vivax malaria, and is one of the core components of the combination therapy recommended by WHO for malaria-endemic areas, covering both adult and pediatric malaria cases.

The global market demand for amodiaquine is highly concentrated in high malaria-endemic regions such as Africa and Southeast Asia. In 2023, the global market size was approximately USD 210 million, with a compound annual growth rate of 4.7% in the past three years. The growth momentum mainly comes from the continuous expansion of antimalarial procurement plans in the public health sector. The current competitive landscape is dominated by generic drug manufacturers, with Indian and Chinese enterprises accounting for more than 85% of the global API supply share. As the original research patent has expired for many years, the market price has remained stable for a long time, and there has been no significant fluctuation.

The original research enterprise of amodiaquine is Sanofi, with the original brand name Camoquin, and the core compound patent expired globally in the 1970s. The originally marketed dosage forms are mainly tablets, with specifications including 150mg and 200mg (calculated as amodiaquine), which have been included in the FDA Reference Listed Drug Catalog, and are also included in the Chinese Pharmacopoeia 2020 Edition. Up to now, the amodiaquine APIs of several domestic enterprises have obtained A status through CDE registration, and domestic amodiaquine preparations have also been approved for marketing and included in the antimalarial drug procurement list. (Data as of May 2025, please refer to the official CDE website for the latest information)

CATO can provide a full range of amodiaquine impurity reference standards. All products meet the regulatory requirements of multiple countries and regions such as the Chinese Pharmacopoeia and the FDA. Most products are regularly in stock, and orders submitted before 16:00 can be shipped on the same day, which can provide stable reference standard supply support for the stages of API R&D, quality research and compliance declaration.